Oryzon Genomics (ORY.MC) Stock Price

Oryzon Genomics Price

BME·CLOSED
2.96EUR-0.03 (-0.94 %)
Market closed

Revenue at Oryzon Genomics has contracted by 46.8% per year over the past 5 years to 20,000.00 EUR. For Oryzon Genomics, the net margin of -26,000.0% is down versus -4,500.0% a few years ago. The consensus 12-month price target for Oryzon Genomics is 5.71 EUR, about 93.1% above where the stock trades today. Of 10 analysts, 9 rate the stock a buy — an overall Buy consensus. The stock trades about 15% above its 52-week low.

Oryzon Genomics stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Oryzon Genomics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Oryzon Genomics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Oryzon Genomics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Oryzon Genomics Stock Price History
DateOryzon Genomics Price
7/24/20262.96 EUR
7/23/20262.99 EUR
7/22/20262.99 EUR
7/21/20262.85 EUR
7/20/20262.84 EUR
7/17/20262.87 EUR
7/16/20262.90 EUR
7/15/20262.89 EUR
7/14/20262.92 EUR
7/13/20262.89 EUR
7/10/20262.88 EUR
7/9/20262.94 EUR
7/8/20262.94 EUR
7/7/20262.96 EUR
7/6/20262.95 EUR
7/3/20262.98 EUR
7/2/20262.97 EUR
7/1/20262.83 EUR
6/30/20263.09 EUR
6/29/20263.11 EUR
6/26/20263.18 EUR
6/25/20263.13 EUR
6/24/20263.18 EUR
6/23/20263.19 EUR
6/22/20263.16 EUR
6/19/20263.14 EUR
6/18/20263.17 EUR
6/17/20263.16 EUR
6/16/20263.13 EUR
6/15/20263.13 EUR
6/12/20263.14 EUR
6/11/20263.12 EUR
6/10/20263.11 EUR
6/9/20262.98 EUR
6/8/20262.97 EUR
6/5/20262.99 EUR
6/4/20263.03 EUR
6/3/20263.03 EUR
6/2/20263.08 EUR
6/1/20263.06 EUR
5/29/20263.14 EUR
5/28/20263.11 EUR
5/27/20263.11 EUR
5/26/20263.10 EUR
5/25/20263.09 EUR
5/22/20263.03 EUR
5/21/20263.03 EUR
5/20/20262.96 EUR
5/19/20262.91 EUR
5/18/20262.95 EUR
5/15/20262.81 EUR
5/14/20262.81 EUR
5/13/20262.75 EUR
5/12/20262.76 EUR
5/11/20262.80 EUR
5/8/20262.73 EUR
5/7/20262.79 EUR
5/6/20262.75 EUR
5/5/20262.75 EUR
5/4/20262.77 EUR
4/30/20262.78 EUR
4/29/20262.75 EUR
4/28/20262.79 EUR
4/27/20262.81 EUR
4/24/20262.79 EUR
4/23/20262.83 EUR
4/22/20262.83 EUR
4/21/20262.83 EUR
4/20/20262.85 EUR
4/17/20262.88 EUR
4/16/20262.87 EUR
4/15/20262.88 EUR
4/14/20262.87 EUR
4/13/20262.81 EUR
4/10/20262.84 EUR
4/9/20262.79 EUR
4/8/20262.80 EUR
4/7/20262.80 EUR
4/2/20262.82 EUR
3/27/20262.68 EUR
3/26/20262.84 EUR
3/25/20262.89 EUR
3/24/20262.79 EUR
3/23/20262.71 EUR
3/20/20262.73 EUR
3/19/20262.76 EUR
3/17/20262.84 EUR
3/16/20262.81 EUR
3/13/20262.82 EUR
3/12/20262.78 EUR
3/11/20262.88 EUR
3/10/20262.93 EUR
3/9/20262.78 EUR
3/6/20262.82 EUR
3/5/20262.85 EUR
2/27/20263.17 EUR
2/26/20263.22 EUR
2/25/20263.16 EUR
2/23/20263.13 EUR
2/20/20263.15 EUR
2/19/20263.15 EUR
2/18/20263.21 EUR
2/17/20263.13 EUR
2/16/20263.15 EUR
2/13/20263.06 EUR
2/12/20263.07 EUR
2/11/20263.11 EUR
2/10/20263.15 EUR
2/9/20263.15 EUR
2/6/20263.12 EUR
2/5/20263.13 EUR
2/4/20263.17 EUR
2/3/20263.18 EUR
2/2/20263.24 EUR
1/30/20263.25 EUR
1/29/20263.25 EUR
1/28/20263.25 EUR
1/27/20263.21 EUR
1/26/20263.21 EUR
1/23/20263.29 EUR
1/22/20263.28 EUR
1/21/20263.12 EUR
1/20/20263.12 EUR
1/19/20263.18 EUR
1/16/20263.22 EUR
1/15/20263.21 EUR
1/14/20263.30 EUR
1/13/20263.30 EUR
1/12/20263.21 EUR
1/9/20263.19 EUR
1/8/20263.23 EUR
1/7/20263.15 EUR
1/6/20263.18 EUR
1/5/20263.22 EUR
1/2/20263.23 EUR
12/31/20253.11 EUR
12/30/20253.12 EUR
12/29/20253.17 EUR
12/24/20253.18 EUR
12/23/20253.11 EUR
12/22/20253.03 EUR
12/19/20253.00 EUR
12/18/20252.98 EUR
12/17/20253.01 EUR
12/16/20253.02 EUR
12/15/20253.09 EUR
12/12/20253.16 EUR
12/11/20253.21 EUR
12/10/20253.24 EUR
12/9/20253.44 EUR
12/8/20253.29 EUR
12/5/20253.21 EUR
12/4/20253.23 EUR
12/3/20253.21 EUR
12/2/20253.20 EUR
12/1/20253.25 EUR
11/28/20253.40 EUR
11/27/20253.31 EUR
11/26/20253.19 EUR
11/25/20253.10 EUR
11/24/20253.07 EUR
11/21/20252.96 EUR
11/20/20252.99 EUR
11/19/20252.99 EUR
11/18/20252.99 EUR
11/17/20253.03 EUR
11/14/20253.07 EUR
11/13/20253.05 EUR
11/12/20252.91 EUR
11/11/20252.86 EUR
11/10/20253.06 EUR
11/7/20253.30 EUR
11/6/20253.41 EUR
11/5/20253.35 EUR
11/4/20253.51 EUR
11/3/20253.54 EUR
10/31/20253.58 EUR
10/30/20253.46 EUR
10/29/20253.47 EUR
10/28/20253.36 EUR
10/27/20253.31 EUR
10/24/20253.24 EUR
10/23/20253.19 EUR
10/22/20253.27 EUR
10/21/20253.23 EUR
10/20/20253.13 EUR
10/17/20253.40 EUR
10/16/20253.53 EUR
10/15/20253.54 EUR
10/14/20253.65 EUR
10/13/20253.91 EUR
10/10/20253.87 EUR
10/9/20253.82 EUR
10/8/20253.45 EUR
10/7/20253.41 EUR
10/6/20253.38 EUR
10/3/20253.23 EUR
10/2/20253.15 EUR
10/1/20252.99 EUR
9/29/20253.01 EUR
9/26/20253.06 EUR
9/25/20253.17 EUR
9/24/20253.38 EUR
9/23/20253.34 EUR
9/22/20253.55 EUR
9/19/20253.23 EUR
9/18/20253.07 EUR
9/17/20252.84 EUR
9/16/20252.79 EUR
9/15/20252.74 EUR
9/12/20252.71 EUR
9/11/20252.73 EUR
9/10/20252.73 EUR
9/9/20252.80 EUR
9/8/20252.72 EUR
9/5/20252.72 EUR
9/4/20252.65 EUR
9/3/20252.64 EUR
9/2/20252.64 EUR
9/1/20252.71 EUR
8/29/20252.69 EUR
8/28/20252.72 EUR
8/27/20252.77 EUR
8/26/20252.83 EUR
8/25/20252.83 EUR
8/22/20252.71 EUR
8/21/20252.58 EUR
8/20/20252.58 EUR
8/19/20252.61 EUR
8/18/20252.67 EUR
8/15/20252.64 EUR
8/14/20252.66 EUR
8/13/20252.65 EUR
8/12/20252.60 EUR
8/11/20252.61 EUR
8/8/20252.63 EUR
8/7/20252.60 EUR
8/6/20252.62 EUR
8/5/20252.64 EUR
8/4/20252.64 EUR
8/1/20252.61 EUR
7/31/20252.65 EUR
7/30/20252.67 EUR
7/29/20252.71 EUR
7/28/20252.72 EUR
Access this data via the Eulerpool API
Get Free API Key

Oryzon Genomics Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2022
0.00 EUR
-5.49 M EUR
-4.23 M EUR
Jan 1, 2023
0.00 EUR
-4.55 M EUR
-3.35 M EUR
Jan 1, 2024
0.00 EUR
-4.42 M EUR
-3.67 M EUR
Jan 1, 2025 (e)
1.92 M EUR
-8.91 M EUR
-2.27 M EUR
Jan 1, 2026 (e)
10.65 M EUR
-3.73 M EUR
1.70 M EUR
Jan 1, 2027 (e)
5.15 M EUR
-15.62 M EUR
-5.11 M EUR
Jan 1, 2028 (e)
112.70 M EUR
88.24 M EUR
48.48 M EUR
Jan 1, 2029 (e)
242.71 M EUR
213.64 M EUR
112.56 M EUR

Oryzon Genomics Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 26, 2026, 8:30 PM
 
REVENUEM EUR
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM EUR
EBITM EUR
EBIT MARGIN%
NET INCOMEM EUR
NET INCOME GROWTH%
SHARESM
20152016201720182019202020212022202320242025e2026e2027e2028e2029e2030e
4.00–––––––––1.0010.005.00112.00242.00541.00
-69.23––––––––––900.00-50.002,140.00116.07123.55
50.00–––––––––-100.00-10.00-20.00-0.89-0.41-0.18
2.00-1.00-1.00-1.00-1.00-1.00-3.00-2.00-1.00-1.00-1.00-1.00-1.00-1.00-1.00-1.00
–-4.00-4.00-2.00-3.00-4.00-7.00-5.00-4.00-4.00-8.00-3.00-15.0088.00213.00491.00
––––––––––-800.00-30.00-300.0078.5788.0290.76
–-5.00-5.00-1.00-3.00-3.00-4.00-4.00-3.00-3.00-2.001.00-5.0048.00112.00255.00
–––-80.00200.00–33.33–-25.00–-33.33-150.00-600.00-1,060.00133.33127.68
27.4927.7233.4838.4545.4952.7652.7655.2960.8864.7564.7564.7564.7564.7564.7564.75
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Oryzon Genomics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Oryzon Genomics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Oryzon Genomics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Oryzon Genomics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Oryzon Genomics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Oryzon Genomics stock margins

The Oryzon Genomics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Oryzon Genomics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Oryzon Genomics.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
-4,700.00 %
- %
- %
Jan 1, 2021
-4,700.00 %
- %
- %
Jan 1, 2022
-4,700.00 %
- %
- %
Jan 1, 2023
-4,700.00 %
- %
- %
Jan 1, 2024
-4,700.00 %
- %
- %
Jan 1, 2025 (e)
-4,700.00 %
-464.33 %
-118.38 %
Jan 1, 2026 (e)
-4,700.00 %
-35.00 %
15.94 %
Jan 1, 2027 (e)
-4,700.00 %
-303.58 %
-99.34 %

Oryzon Genomics Stock Revenue, EBIT, Earnings per Share

The Oryzon Genomics earnings per share therefore indicates how much revenue Oryzon Genomics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2020
0.00 EUR
-0.08 EUR
-0.06 EUR
Jan 1, 2021
0.00 EUR
-0.13 EUR
-0.09 EUR
Jan 1, 2022
0.00 EUR
-0.10 EUR
-0.08 EUR
Jan 1, 2023
0.00 EUR
-0.07 EUR
-0.06 EUR
Jan 1, 2024
0.00 EUR
-0.07 EUR
-0.06 EUR
Jan 1, 2025 (e)
0.03 EUR
-0.14 EUR
-0.04 EUR
Jan 1, 2026 (e)
0.16 EUR
-0.06 EUR
0.03 EUR
Jan 1, 2027 (e)
0.08 EUR
-0.24 EUR
-0.08 EUR

Oryzon Genomics business model & stock analysis

The company Oryzon Genomics SA is a biopharmaceutical company that was founded in 2000 in Barcelona, Spain. Since then, the company has gained a growing reputation for the development of innovative therapeutic approaches for serious diseases. Oryzon works on the development of epigenetic products that focus on molecular docking sites in the cell to modulate approved proteins and fragments. They use a unique technology called ORY-1001 to promote tumor apoptosis. The technology involves the use of epigenetic modulators to develop therapeutic approaches for certain types of cancer such as CLL and leukemia. Oryzon operates various divisions such as Research and Development, Intellectual Property, and Product Development. Within Research and Development, they work on the research and development of new technologies and products. They also have a portfolio of patented and potential patent applications in the field of epigenetics and products for the treatment of various types of cancer, neurodegenerative diseases such as Alzheimer's, and schizophrenia. The Intellectual Property division is responsible for all of Oryzon's patent rights. They review all of Oryzon's patents to ensure they meet the highest standards of patent law. The Product Development department helps the company in transferring newly developed products into effective and approved drugs. They also assist in the approval process by health authorities, particularly in the field of clinical trials. At the beginning of 2020, Oryzon announced that they will start a Phase 2 clinical trial for their product line ORY-2001 for the treatment of Alzheimer's patients. ORY-2001 is a selective histone deacetylase (HDAC) inhibitor aimed at slowing down the pathological process of Alzheimer's and other neurodegenerative diseases. This technology has the potential to improve the lives of millions of patients worldwide. In 2017, the company acquired WNT research from Inthera Bioscience SA, a biotechnology company focused on cancer treatment. The acquisition expanded Oryzon Genomics' portfolio to develop new innovative cancer therapies. The field of epigenetics is considered a rising and promising area in the medical industry. Oryzon Genomics has successfully positioned itself as a leading company in this field and continues to work on developing innovative solutions for the treatment of life-threatening diseases. The company remains a company to watch in the biopharmaceutical industry in the coming years.

Oryzon Genomics SWOT Analysis

Strengths

Oryzon Genomics SA has several key strengths that contribute to its competitive advantage:

  • Strong research and development capabilities, enabling the company to innovate and develop new products.
  • A solid portfolio of intellectual property rights, providing protection for its discoveries and technologies.
  • Well-established partnerships and collaborations with academic and industry experts, fostering knowledge exchange and opportunities for growth.
  • Robust financial position, allowing investment in cutting-edge technologies and expansion into new markets.
  • Successful track record in achieving regulatory approvals and commercializing products.

Weaknesses

Despite its strengths, Oryzon Genomics SA also faces certain weaknesses:

  • Reliance on a limited number of key products or pipeline candidates, posing risks associated with dependency.
  • Dependency on collaborations and partnerships for research and development, potentially limiting control over decision-making processes.
  • Significant investments required for product development and clinical trials, placing financial strain on the company.
  • Limited marketing and commercialization capabilities, potentially affecting market penetration and revenue generation.
  • Susceptibility to regulatory changes and uncertainties within the biotechnology industry.

Opportunities

Oryzon Genomics SA can capitalize on the following opportunities in the market:

  • Growing global demand for innovative therapies and personalized medicine, opening up new revenue streams.
  • Expansion into emerging markets with favorable regulatory environments, facilitating market entry and growth.
  • Potential collaborations and partnerships with pharmaceutical giants, providing access to additional resources and expertise.
  • Advancements in technology and data analytics, enabling improved therapeutic targeting and personalized treatment options.
  • Increased focus on neurodegenerative diseases and mental health, aligning with Oryzon's areas of expertise.

Threats

Oryzon Genomics SA should be aware of the following threats in the competitive landscape:

  • Intense competition from other biotechnology companies and established pharmaceutical players.
  • Stringent regulatory requirements and complex approval processes, leading to potential delays and increased costs.
  • Rapidly evolving technological advancements, necessitating continuous investment to stay ahead.
  • Intellectual property challenges and potential infringements from competitors.
  • Economic downturns and market volatility affecting funding and investment opportunities.

Oryzon Genomics Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Oryzon Genomics historical P/E ratio, EBIT multiple, and P/S ratio

Oryzon Genomics annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Oryzon Genomics shares outstanding

The number of shares of Oryzon Genomics was 64.75 M in 2025. This indicates how many shares Oryzon Genomics is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2020
52.76 M Stocks
Jan 1, 2021
52.76 M Stocks
Jan 1, 2022
55.29 M Stocks
Jan 1, 2023
60.88 M Stocks
Jan 1, 2024
64.75 M Stocks
Jan 1, 2025 (e)
64.75 M Stocks
Jan 1, 2026 (e)
64.75 M Stocks
Jan 1, 2027 (e)
64.75 M Stocks

Current Oryzon Genomics forecasts and price targets in July 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy90.00 % (9)
Hold10.00 % (1)
Sell0.00 % (0)
12M Price Target
5.71
Last Price
2.96
Currency
EUR
12M Return Potential
93.10 %
LTM Return
0 %

Oryzon Genomics Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
7/20/2023-0.00EUR-EUR2023 Q2
5/3/2023-0.04EUR-EUR2023 Q1
2/6/2023-0.06EUR0.00EUR2022 Q4
11/2/2022-0.05EUR0.00EUR2022 Q3
7/22/2022-0.02EUR0.00EUR2022 Q2
5/5/2022-0.04EUR0.00EUR2022 Q1
2/7/2022-0.04EUR0.00EUR2021 Q4
10/28/2021-0.03EUR0.00EUR2021 Q3
7/29/2021-0.03EUR0.00EUR2021 Q2
5/7/2021-0.02EUR0.00EUR2021 Q1

EESG©

Eulerpool ESG Scorecard© for the Oryzon Genomics stock

81/100
88
Environment
99
Social
56
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Oryzon Genomics shareholder structure

% Name
10.88003%
Buesa Arjol (Carlos Manuel)
Buesa Arjol (Carlos Manuel)
7.69928%
Maes (Tamara)
Maes (Tamara)
5.27293%
Ventura Ferrero (Jose Maria)
Ventura Ferrero (Jose Maria)
3.99963%
Heights Capital Management, Inc.
Heights Capital Management, Inc.
1.92020%
Echarri Torres (Josep Maria)
Echarri Torres (Josep Maria)
0.15506%
Andbank Wealth Management, SGIIC, S.A.U.
Andbank Wealth Management, SGIIC, S.A.U.

Oryzon Genomics Executives and Management Board

DA

Don Carlos Manuel Buesa Arjol

Executive Chairman of the Board, Chief Executive Officer · since 2002

Compensation478,000.00 EUR
DL

Don Manuel Oscar Lopez-Figueroa

Lead Independent Director

Compensation65,000.00 EUR
DM

Don Antonio Fornieles Melero

Independent Director

Compensation54,000.00 EUR
DR

Don Ramon Adell Ramon

(67)

Independent Director

Compensation50,000.00 EUR
DN

Dna. Isabel Aguilera Navarro

(64)

Independent Director

Compensation50,000.00 EUR

Oryzon Genomics Supply Chain

Frequently asked questions about Oryzon Genomics

The business model of Oryzon Genomics SA revolves around the development and commercialization of innovative epigenetic therapies. As a biopharmaceutical company, Oryzon focuses on the research and discovery of new drugs to treat diseases associated with altered gene expression. By targeting specific epigenetic marks, they aim to regulate gene activity and restore normal cellular function. Oryzon Genomics SA collaborates with academic institutions and pharmaceutical companies to advance their therapies through preclinical and clinical development stages. With a focus on epigenetics, Oryzon strives to provide novel therapeutic solutions for diseases such as cancer, neurological disorders, and autoimmune conditions.

All fundamentals and in-depth analysis of Oryzon Genomics

Our stock analysis for Oryzon Genomics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Oryzon Genomics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Oryzon Genomics Stock
Oryzon Genomics Revenue→
Oryzon Genomics Stock
Oryzon Genomics Net Income→
Oryzon Genomics Stock
Oryzon Genomics P/E→
Oryzon Genomics Stock
Oryzon Genomics P/S→
Oryzon Genomics Stock
Oryzon Genomics EBIT→
Oryzon Genomics Stock
Oryzon Genomics Dividend→
Oryzon Genomics Stock
Oryzon Genomics Directors Dealings→
Oryzon Genomics Stock
Oryzon Genomics Stocks→
Oryzon Genomics Stock
Oryzon Genomics Market capitalization→
Oryzon Genomics Stock
Oryzon Genomics Debt→
Oryzon Genomics Stock
Oryzon Genomics Liabilities→
Oryzon Genomics Stock
Oryzon Genomics Equity→
Oryzon Genomics Stock
Oryzon Genomics AAQS→
Oryzon Genomics Stock
Oryzon Genomics Employees→
Oryzon Genomics Stock
Oryzon Genomics ROE→
Oryzon Genomics Stock
Oryzon Genomics ROA→
Oryzon Genomics Stock
Oryzon Genomics ROCE→
Oryzon Genomics Stock
Oryzon Genomics News→
Oryzon Genomics Stock
Oryzon Genomics Analyst Price Targets→

Health Stocks

OS TherapiesOruka TherapeuticsOscotecOrtivusOSE ImmunotherapeuticsOrtin GlobalOssDsignOrthoPediatricsOsteonic CoOrthometrixOsteoporeOrthofix MedicalAll Stocks A–Z →